More Uncertainty For Biopharma Players As China Economic Growth Falters
30% Of EU Businesses Report Revenue Decline
China's faltering macro economic steam indicates a slowdown in consumption and a lack of new growth engines, adding further woes to an already challenging environment for international players in the biopharma sector.
